Wappa: medical marijuana from two manufacturers

What is Wappa and where does it come from?

It is unknown which parents Wappa inherited its composition from. Available descriptions consistently classify it as a hybrid with an indica dominance, but none of them indicate the parental strain pair. The declared THC content, considering the manufacturer's tolerance, ranges from 19.8% to 24.2%. The name itself does not determine its origin.

The note about the uncertain pedigree is not a gap in our database, but a state of public sources. The name Wappa functions in the Paradise Seeds catalog, but belonging to a breeding line does not replace information about the parental strain pair. Reconstructing it from the sound of the name would create false relationships, which is why we leave this field blank and state it directly.

Accordingly, the classification is as follows: descriptions assign Wappa to hybrids with an indica dominance. This is a descriptive category, not a measurement result, so it speaks more about how the strain is positioned in catalogs rather than what is found in a specific batch of dried flower.

In Polish pharmacies, Wappa is available as dried flower in the Rpw category, which means a pharmaceutical raw material dispensed by a doctor's prescription. What exactly is contained in the package is determined by the analysis certificate attached to the batch, not the strain name visible on the label. The range of content mentioned above comes from the fact that the manufacturer's declaration allows for deviation in both directions, so a single number would be a false precision.

Which manufacturers supply Wappa to Polish pharmacies?

Two: S-LAB and Synoptis Pharma. Both companies introduce the dried flower under the same strain name, in the same dispensing category. However, publicly available materials do not describe how one manufacturer's version differs from the other's, and that is an honest answer to the question about differences. The current list of packages is maintained by the cluster hub.

Producer	Dispensing category	What is known about this version
S-LAB	Rpw, prescription only	Dried flower under the name Wappa; the description of the version is limited to the strain name and declared content, without a separate characteristic of the batch
Synoptis Pharma	Rpw, prescription only	Dried flower under the name Wappa; materials do not indicate that the terpene composition is marked and published separately for each batch

The strain name in this arrangement is not a guarantee of the raw material's identity. The same cultivar managed by two different growers, in a different cycle and with a different drying method, produces batches with varying proportions of individual terpenes. Therefore, the comparison above states who supplies Wappa, not that both versions are interchangeable.

The availability range changes throughout the year and is not a feature of the strain. A batch disappears from circulation when the series ends and returns when the manufacturer releases another; between one moment and the next, the pharmacy simply will not dispense it. For this reason, this text does not contain either a list of packages or rates: the current assortment is maintained by a comparison of strains available in Polish pharmacies, and it is worth checking the status there today.

The remaining entries from both companies gather separate listings: a catalog overview S-LAB and a catalog overview Synoptis Pharma.

How does Wappa smell and taste?

Fruity-berry, with a distinct note of mandarin and a skunky background that reveals its origin from the Paradise Seeds line. It is this fruity direction that distinguishes Wappa from dried flowers described as bread-citrus, although the scent remains a descriptive impression rather than a measurement result. The nose decides here earlier than the table.

The composition given for this strain includes five items: humulene, caryophyllene, linalool, myrcene and pinene. We consciously do not add a percentage share to any of these entries. Databases publish numbers without a common denominator, and the sums of the same sets sometimes fall far below the whole, sometimes much closer to it, so the share next to the compound name would pretend to be a measurement that no one has performed in a comparable way.

This composition describes one source, the Polish database budcare.pl, and there is nothing to compare it with. For strains described by two databases, there is usually a discrepancy in the order of terpenes; here such control is simply lacking, so the list above should be read as a report from one publisher, not as a market consensus.

There is no simple correlation between scent and the list of compounds. The tangerine note is associated with the citrus fraction, while in the given composition, caryophyllene leads, which is rather attributed to pepper and wood. The discrepancy arises because the olfactory impression is also determined by compounds present in trace amounts, which routine testing does not cover at all.

How long does it take for Wappa to start working and how long does the effect last?

Depending on the route of administration, not the strain. Vaporization provides the first sensations within a few minutes and concludes the episode that same evening, while oral administration delays the onset by hours and similarly prolongs the end. No measurement has been published for Wappa that would change this picture. Therefore, the following description pertains to the route that the raw material takes in the body.

The route of administration determines the course more than the variety itself. After vaporization, the substance passes from the lungs to the blood almost immediately, so the first sensations appear after a few minutes, the intensity increases for another ten to thirty minutes, and the whole effect lasts for two to four hours. After ingestion, the raw material first passes through the intestine and liver, so the first sensations are awaited from half an hour to two hours, and the episode can last six, sometimes eight hours. Hence the most common mistake with oral administration: anyone who thinks nothing is happening after thirty minutes and takes another dose will receive both doses at once. The above ranges describe the route of administration, not this variety; pharmacokinetic studies for a single cultivar have not been published.

The practical conclusion for this strain is brief: the composition of Wappa does not shorten or prolong the above intervals, as they are determined by the absorption method, not the character of the aroma. The raw material issued in Polish pharmacies in the Rpw category is dried flower intended for vaporization, so patients usually follow the first of the described paths.

What is known, and what is not known about the effects of this strain?

There are no studies on Wappa itself. What can be cited pertains to caryophyllene, the leading terpene in its profile, and comes from studies on mice and receptor binding tests. Everything else is user reports or manufacturer material. Distinguishing between these two orders is more important here than the length of the list.

The first study, by the Gertsch team from 2008 in the Proceedings of the National Academy of Sciences (PMID:18574142), showed that (E)-caryophyllene selectively bound to the CB2 receptor with a constant Ki of 155 nM and inhibited paw swelling induced by carrageenan in wild-type mice, but not in animals lacking the CB2 receptor. This indicates a CB2-dependent mechanism. The study did not include any anxiety tests, although such a conclusion is sometimes attributed to it.

The second study, by the Klauke team from 2014 in European Neuropsychopharmacology (PMID:24210682), investigated oral caryophyllene in mice. The compound reduced the late, inflammatory phase of pain in the formalin test in a CB2 receptor-dependent manner, with no effect on the early phase, and in a neuropathic pain model, it alleviated thermal hyperalgesia and mechanical allodynia without developing tolerance with chronic administration.

The boundary of these two studies should be placed exactly where the authors place it.

Neither of the two studies tested caryophyllene on humans or in inhaled form from dried flower; both studies pertain to oral or systemic administration in mice in pain and inflammation models, not sleep or mood.

The rest of what circulates about Wappa has a different status. Descriptions of mood after a session, times of day, or comparisons with other strains come from user reports and catalog descriptions, not from studies with a control group. This does not mean they are fabricated; it means they cannot be verified or repeated, and they should be read as such. This is more broadly covered in an entry about kariofilenie.

What side effects have been reported for this strain?

None specifically attributed to it. Safety monitoring is conducted for medicinal products identified by batch number, and the name of the cultivar is not a reporting unit in this system. Reports after Wappa dried flower thus fall into the pool describing hemp dried flower as a whole group of raw materials. Below is what results from this pool.

Reports of adverse effects are collected for medicinal products with a batch number, not for the strain name, so the following pertains to hemp dried flower as a group of raw materials. The most frequently reported symptoms are dry mouth, red eyes, and increased heart rate. Dizziness upon rapid standing, daytime drowsiness, and temporary worsening of short-term memory are less frequently described, as well as anxiety that increases with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide the frequency of these symptoms numerically, as public compilations for hemp dried flower in Poland do not separate them by individual products.

For Wappa, nothing separate can be derived from this compilation, and it should be read as such. The reporting path goes through the attending physician or directly to the monitoring system for adverse effects of medicinal products, and the reference point remains the batch number from the packaging, not the strain name on the label.

At what temperature should this strain be vaporized?

There is no single correct value for Wappa, and we do not provide any. What we have are boiling points of pure compounds: caryophyllene, leading in this profile, boils only above 256 degrees Celsius, while myrcene at around 167. However, the number itself says less than it seems, and below it is broken down into caveats.

Lower settings first extract the more volatile fractions, namely in this composition myrcene and pinene, making the vapor lighter in perception and less pronounced in taste. Higher settings reach for humulene and caryophyllene, along with a greater load of the cannabinoid itself; the risk of burning the material also increases, after which only smoke remains from the fruity aroma.

However, the tables themselves are not consistent. The boiling temperatures given for the same compounds differ between compilations to such an extent that a setting chosen for one of them diverges from the other; a separate entry shows, where do these discrepancies come from.

Moreover, the setting on the display is not the temperature of the dried flower in the chamber. The discrepancy between the device's reading and what happens to the material can be significant and depends on the design of the vaporizer as well as how tightly packed the load is; this is described in the entry about the difference between the setting and the temperature of the raw material. The order in which aromatic compounds leave the dried flower is also distributed wpis o ich odparowywaniu.

Which strains are related to Wappa?

None that can be proven. Without an established parental pair, there is no basis for sibling relationships, and assigning them based on similarly sounding names would lead to connections without breeding support. The empty field here is a result, not a lack of data. Therefore, there is no list of sister strains below.

The pedigree chart in this collection connects strains only where sources provide specific parents. Wappa is not included because its origin remains undetermined. Adding its relatives based on intuition would be the worst possible solution: the reader would receive a connection that appears factual, but is actually based on similarities in the letters of the name.

Instead of comparing it to siblings, it makes more sense to compare it based on measurable factors. The first point of reference is the leading terpene: strains in which caryophyllene also comes to the forefront of the profile are compared osobny wpis. The second is the manufacturer, as the catalog of one company can be stylistically more consistent than a random set of cultivars with a common ancestor.

The third point of reference remains the availability list itself. A complete compilation of strains available in Polish pharmacies, along with manufacturers and the leading terpene, can be found in the overview of currently available medical marijuana strains.. From there, it is easier to find dried flower with a similar composition than from the name Wappa itself, which does not lead anywhere further.

Frequently asked questions about the Wappa strain.

Is the pedigree of the Wappa strain known?

No. Available sources do not provide a pair of parental strains, and the classification is limited to defining it as a hybrid with an indica dominance. Reconstructing its origin based on the name's sound would create false connections, which is why the pedigree field remains empty in this description, and this is information, not a gap.

Which terpene leads in the profile of the Wappa strain?

Caryophyllene. Alongside it, the listed composition includes humulene, linalool, myrcene, and pinene. We do not provide percentage shares next to these names because databases publish numbers without a common denominator, and totals for the same sets vary between sources. The composition itself is described by one source.

What THC content is declared for the Wappa strain?

It ranges from 19.8% to 24.2%. We provide a range, not a single number, because the manufacturer's declaration allows for deviation in both directions; a single value would suggest precision that the batch of dried flower does not have and cannot have. Each batch has its own certificate of analysis, and that determines the outcome.

Does the Wappa strain have siblings available in Polish pharmacies?

This cannot be established. Siblings are derived from a parental pair, and this is not documented for Wappa, so the list remains empty. Comparisons should be sought based on the leading terpene or the manufacturer, as these characteristics are described and verifiable. A common part of the name proves nothing here.

Has the effect of the Wappa strain itself been studied?

No. The publications that can be cited here concern caryophyllene administered to mice, not the dried flower of that name. Transferring their conclusions to a patient vaporizing Wappa would be an overinterpretation, as both the species and the route of administration differ. Both studies are described above along with what they did not demonstrate.

Is Wappa consistently available in pharmacies?

No. Availability depends on whether the manufacturer currently has a released batch, so the strain can disappear from circulation for weeks and return without notice. The status on a given day shows the compilation of available strains, updated independently of this description. The pharmacy dispenses it only with a prescription in the Rpw category.

Dried flower is a pharmaceutical raw material dispensed by a doctor's prescription in the Rpw category. The above text is for informational purposes and does not replace medical consultation.